Ready. Raise. Rise. Campaign

Bristol-Myers SquibbThe Ready. Raise. Rise. campaign encourages everyone to raise and share a flag to salute those who have been touched by cancer, especially patients and caregivers, and learn more about a rapidly evolving area of research, Immuno-Oncology, which seeks to harness the body's own immune system to fight cancer. For the campaign’s second year, Eric Stonestreet of television's hit comedy "Modern Family" and films "Confirmation" and "The Secret Life of Pets" is joined by his mother Jamey, who faced and survived cancer twice. Bristol-Myers Squibb sponsors the campaign, which inspired people to raise more than 50,000 flags last year, and this year will make charitable donations to 23 participating cancer support groups on behalf of flag raisers.

"My mom has survived cancer twice, so I have personal reasons for standing with Ready. Raise. Rise. again this year - It gives me a chance to say how much I admire heroes like her, and at the same time it allows me to learn about promising research in the fight against cancer, like Immuno-Oncology. And participating in the campaign also supports cancer advocacy groups that are helping others like my mom," said Eric Stonestreet. "So mom and I are asking you to be Ready to Raise a virtual flag and Rise in celebration of patients, caregivers and anyone else you know whose life is touched by cancer."

With more than 32 million people living with cancer worldwide, nearly every family is impacted by cancer. Stonestreet is asking people to go to ReadyRaiseRise.com to create and share a flag in honor of someone who has been affected by cancer - whether it be themselves, a loved one or a caregiver. Each person who raises a flag can select one of 23 cancer advocacy organizations they wish to support and share their flag on social media using the hashtag #RaiseYourFlag. For each flag raised and shared, the selected organization will receive a charitable donation from Bristol-Myers Squibb. The company will distribute up to a total of $150,000 in charitable donations across participating organizations. Both Stonestreet and his mother are featured in a public service announcement to further extend the reach of the educational information about Immuno-Oncology research.

"Immuno-Oncology is an innovative area of research that may be changing the way we approach cancer," said Sanjiv Agarwala, MD, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, PA, and professor of medicine at Temple University School of Medicine in Philadelphia, PA. "I'm passionate about educating the cancer community about Immuno-Oncology research as it explores a different way to approach cancer treatment, and that may allow patients with advanced cancer the potential to lead longer lives."

"Ready. Raise. Rise. continues to resonate with the cancer community, further motivating us to relentlessly pursue Immuno-Oncology research and make a difference for patients," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our ultimate goal with Immuno-Oncology is to improve survival and quality of life for patients living with various types of cancer, and this program provides an inspiring platform to honor patients and caregivers in a meaningful way."

Immuno-Oncology at Bristol-Myers Squibb
Bristol-Myers Squibb is leading research in an innovative field of cancer research and treatment known as Immuno-Oncology, which involves agents whose primary mechanism is to work directly with the body’s immune system to fight cancer. The company is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, including researching the potential of combining Immuno-Oncology agents that target different pathways in the treatment of cancer.

Bristol-Myers Squibb is committed to advancing the science of Immuno-Oncology, with the goal of changing survival expectations and the way patients live with cancer.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]